Virtual Tumor Board

Neal Shore, MD; Sam Chang, MD, MBA; Max Kates, MD; and Katie Murray, DO, MS, discuss how the recent FDA approval of UGN-102 (mitomycin gel) provides a paradigm-shifting ablative treatment option for patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC), offering an alternative to repetitive surgical resections and potentially reducing the treatment burden through its sustained-release formulation that achieved 80% complete response rates in the ENVISION trial.

Ashish Kamat, MD, MBBS; Sam Chang, MD, MBA; Bogdana Schmidt, MD, MPH; and Katie Murray, DO, MS, discuss how management of non–muscle-invasive bladder cancer (NMIBC) requires careful risk stratification, standardized BCG therapy protocols, consideration of alternative treatments for BCG-unresponsive disease, gender-specific approaches, and specialized care for younger patients to improve outcomes and quality of life.

Panelists review four 4 clinical cases, discussing guideline-directed approaches to new and emerging treatment approaches in patients with hormone-sensitive and castration-resistant prostate cancer, as well as share sharing perspectives on key clinical trial data that may impact our decisions.

A panel of expert oncologists review clinical cases and provide a comprehensive discussion on the recent clinical advances in PSMA PET imaging for prostate cancer.

A panel of urology experts discuss advances in prostate cancer imaging and how it informs providers and influences patient care decision-making while reviewing several patient profiles.